| Literature DB >> 32360592 |
Michela Fagiolini1, Annarita Patrizi2, Jocelyn LeBlanc2, Lee-Way Jin3, Izumi Maezawa3, Sarah Sinnett4, Steven J Gray4, Sophie Molholm5, John J Foxe6, Michael V Johnston7, Sakkubai Naidu7, Mary Blue7, Ahamed Hossain7, Shilpa Kadam7, Xinyu Zhao8, Quiang Chang8, Zhaolan Zhou9, Huda Zoghbi10.
Abstract
Disruptions in the gene encoding methyl-CpG binding protein 2 (MECP2) underlie complex neurodevelopmental disorders including Rett Syndrome (RTT), MECP2 duplication disorder, intellectual disabilities, and autism. Significant progress has been made on the molecular and cellular basis of MECP2-related disorders providing a new framework for understanding how altered epigenetic landscape can derail the formation and refinement of neuronal circuits in early postnatal life and proper neurological function. This review will summarize selected major findings from the past years and particularly highlight the integrated and multidisciplinary work done at eight NIH-funded Intellectual and Developmental Disabilities Research Centers (IDDRC) across the US. Finally, we will outline a path forward with identification of reliable biomarkers and outcome measures, longitudinal preclinical and clinical studies, reproducibility of results across centers as a synergistic effort to decode and treat the pathogenesis of the complex MeCP2 disorders.Entities:
Keywords: animal models; biomarkers; neurodevelopmental disorders; signaling pathways; translational
Mesh:
Substances:
Year: 2020 PMID: 32360592 PMCID: PMC8025698 DOI: 10.1016/j.neuroscience.2020.04.037
Source DB: PubMed Journal: Neuroscience ISSN: 0306-4522 Impact factor: 3.590